Biologicals ( IF 1.7 ) Pub Date : 2020-08-25 , DOI: 10.1016/j.biologicals.2020.08.007 Amin Azimi 1 , Sheida Heidarian 2 , Homa Zamani 3 , Nastaran Taleghani 1 , Mohsen Dehghani 1 , Ehsan Seyedjafari 1
Adjuvants are a crucial component of recombinant vaccines such as the human papillomavirus (HPV) vaccine. Monophosphoryl lipid A (MPL) extracted from Salmonella Minnesota lipopolysaccharide is used as an adjuvant for the HPV vaccine. Due to the limitations in accessibility and reproducibility of MPL, investigating synthetic analogues of MPL (synMPL) is urgently needed to overcome these limitations. In this study, female BALB/c mice were vaccinated by HPV vaccine formulated with synMPL and aluminum hydroxide gel in which the concentration of synMPL ranged from 0 to 100 μg/dose. Anti-HPV L1 VLP antibody was measured for each group through Indirect ELISA and compared with Cervarix and Gardasil vaccines as approved anti-HPV vaccines. SynMPL showed a concentration-dependent increase up to 50 μg/dose in the immunogenicity of the vaccine. Therefore, synMPL at concentration of 50 μg/dose was selected as optimum concentration. The GMT profiling of synMPL-formulated vaccine (named Papilloguard) and Cervarix was not statistically different (Mann-Whitney test). The Gardasil vaccine showed 10-fold lower GMT for anti-HPV 18 L1 VLP antibody but anti-HPV 16 L1 VLP antibody was similar to Cervarix and Papilloguard. The current findings suggest that the synMPL in combination with aluminum hydroxide could be used as a potential adjuvant candidate for human vaccine.
中文翻译:
单磷酰脂质 A 合成类似物的优化剂量作为配制重组人乳头瘤病毒疫苗的有效替代品。
佐剂是重组疫苗的重要组成部分,例如人乳头瘤病毒 (HPV) 疫苗。从明尼苏达州沙门氏菌中提取的单磷酰脂质 A (MPL)脂多糖用作HPV疫苗的佐剂。由于 MPL 的可访问性和可重复性的限制,迫切需要研究 MPL 的合成类似物 (synMPL) 以克服这些限制。在本研究中,雌性BALB/c小鼠接种了由synMPL和氢氧化铝凝胶配制的HPV疫苗,其中synMPL的浓度范围为0至100μg/剂。通过间接ELISA测量每组的抗HPV L1 VLP抗体,并与作为批准的抗HPV疫苗的Cervarix和Gardasil疫苗进行比较。SynMPL 显示疫苗的免疫原性浓度依赖性增加高达 50 μg/剂量。因此,选择浓度为50 μg/剂量的synMPL 作为最佳浓度。SynMPL 配制的疫苗(命名为 Papilloguard)和 Cervarix 的 GMT 分析没有统计学差异(Mann-Whitney 检验)。Gardasil 疫苗显示抗 HPV 18 L1 VLP 抗体的 GMT 降低了 10 倍,但抗 HPV 16 L1 VLP 抗体与 Cervarix 和 Papilloguard 相似。目前的研究结果表明,synMPL 与氢氧化铝的组合可用作人类疫苗的潜在佐剂候选物。